Tobias Boettler et al.: "SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis"; Liver inflammation is observed during SARS-CoV-2 infection but can occur in some individuals after vaccine

COVID19 vaccination can elicit a distinct T cell-dominant immune-mediated hepatitis

This study adds to the growing evidence that the COVID vaccine is provoking hepatitis and is a serious cause for concern. What these emerging cases tell us is that the vaccine companies did not do the proper safety study or duration of follow-up post vaccine in their studies. You cannot take a 12-15 year vaccine study process and boil it down to 4 months and expect to tell me that you did ‘safety assessment’. These vaccine makers did no proper safety testing and it is showing now in the adverse reporting.

SOURCE:

SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis

Key details:

‘The case of a 52-year-old male, presenting with bimodal episodes of acute hepatitis, each occurring 2-3 weeks after BNT162b2 mRNA vaccination and sought to identify the underlying immune correlates. The patient received first oral budesonide, relapsed, but achieved remission under systemic steroids.

Analysis of the hepatic tissue revealed an immune infiltrate quantitatively dominated by activated cytotoxic CD8 T cells with panlobular distribution. An enrichment of CD4 T cells, B cells, plasma cells and myeloid cells was also observed compared to controls.

COVID19 vaccination can elicit a distinct T cell-dominant immune-mediated hepatitis with a unique patho-mechanism associated with vaccination induced antigen-specific tissue-resident immunity requiring systemic immunosuppression.

COVID19 vaccination can elicit a distinct T cell-dominant immune-mediated hepatitis with a unique patho-mechanism associated with vaccination induced antigen-specific tissue-resident immunity requiring systemic immunosuppression.’

Key passage:

“Autoimmune-hepatitis-like disease after vaccination against SARS-CoV-2 is now recognized as a rare adverse event not identified in early trials. The widespread use of the vaccine with administration of hundreds of million doses worldwide raises also questions of causality vs. coincidence. In particular, AIH-like disease after vaccination was reported in patients with age and gender characteristics typical for spontaneous AIH[6, 7, 10]. While some of these cases thus may represent coincidence, a causal relationship to the vaccine is also possible, such as bystander hepatitis driven by elevation of systemic cytokines or chemokines after vaccination, similar to cases occurring in association with natural SARS-CoV-2 infection[13]. The varying patterns of clinical manifestation and the wide range of time elapsed between vaccine administration and symptom onset clearly suggest that different mechanisms may contribute to these reported cases. Here, our analysis highlights that activated cytotoxic CD8 T cells including vaccine-induced spike-specific CD8 T cells could contribute to disease pathogenesis.

Importantly, autoimmune hepatitis is a condition that requires lifelong immunosuppressive therapy in many affected patients[16]. It is therefore important to differentiate AIH from possibly transient immune-mediated hepatitis post vaccination.”